Latest Share Chat

REMOVE ADS

Glaxosmithkline Share News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

1,903.50 -9.50 (-0.50%)

Bid:

1,904.00

Ask:

1,905.00

Spread: 1.00 (0.053%)

Market Cap: £76.34b

Last checked at -

Intraday Glaxosmithkline Share Chart

REMOVE ADS

Glaxosmithkline News

GSK stresses need for innovation as herpes vaccine fails to progress

(Alliance News) - GSK PLC on Wednesday said that its vaccine candidate for the herpes simplex virus did not meet a primary efficacy objective in testi...

GSK's herpes vaccine candidate fails to meet primary efficacy objective

(Sharecast News) - Drugmaker GSK said on Wednesday that primary objective data analysts from a phase II trial of its early-stage therapeutic herpes si...

TRADING UPDATES: Live Co fails to reach agreement with creditor

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

EXECUTIVE CHANGES: Invinity replaces CEO; Gulf Keystone chair dies

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and Friday and not separatel...

GSK hails positive results of Nucala clinical trials in lung disease

(Alliance News) - GSK PLC on Friday announced positive headline results of the Matinee phase III clinical trial evaluating Nucala.

GSK announces positive COPD trial results

(Sharecast News) - GSK announced positive results from its phase three 'MATINEE' clinical trial on Friday, which evaluated the effectiveness of 'Nucal...

LONDON MARKET MIDDAY: Stocks tick higher as investors prep for US GDP

(Alliance News) - Stock prices in London were higher at midday on Thursday, as the market looks ahead to a handful of economic data from the US later ...

TOP NEWS: GSK hails EU approval of RSV jab Arexy for 50-59 year olds

(Alliance News) - GSK PLC on Thursday announced that the European Commission has authorised Arexvy, its respiratory syncytial virus vaccine, for adult...